At a glance
ClinicalIndex Comparison RecordN/ACompleted· 113 enrolled
Drug / intervention
Brentuximab vedotin (Genetical Recombination)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Use Surveillance for ADCETRIS Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
In Brief
An observational study evaluating Brentuximab vedotin (Genetical Recombination) for Untreated CD30-Positive Hodgkin's Lymphoma. Completed, enrolled 113 participants across 1 site.
Detailed Summary
The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionSep 2023
TodayJul 2026
First PostedNov 2, 2018
Enrollment StartNov 1, 2018
Primary CompletionSep 27, 2023
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.7 years ago
Interventions
Brentuximab vedotin (Genetical Recombination)drug
Brentuximab vedotin Intravenous Infusion